L’Oreal Settles With FTC Over Gene-Related Anti-Aging Skin-Care Claims
This article was originally published in The Rose Sheet
A proposed consent agreement between L’Oreal USA and the Federal Trade Commission bars the company from claiming that skin-care products from its Lancome and L’Oreal Paris brands target users’ genes to award anti-aging benefits. The settlement, which is subject to public comment and final FTC approval, follows a 2012 warning letter from FDA that cited some of the same marketing claims.
You may also be interested in...
The estimated $700,000 settlement puts to rest allegations that the luxury skin-care firm deceived consumers with claims about its PhytoCellTec ingredient’s ability to slow the aging process. G.M. Collin, another PhytoCellTec Malus Domestica user, also appears to have reached a deal with plaintiffs in litigation challenging its anti-aging claims.
Plant stem cell actives such as Mibelle Biochemistry's PhytoCellTec Malus Domestica were marquee ingredients for skin-care brands in the flourishing US anti-aging market years back. But what once was fruitful has turned rotten with regulatory crackdowns in recent years and class actions that continue to weigh on product manufacturers.
Class-action suits against beauty firms on the rise as industry pushes the envelope with claims and FDA warning letters draw attention from class-action law firms, legal experts note. Hogan Lovells attorney Mark Goodman says: “I don’t see this [trend] going away anytime soon.”